Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 2/20 | 0.47 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825858 | 0.87 | KDM4E (0.52) | KDM4EMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4833599 | 0.86 | KDM4E (0.50) | KDM4EMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4825849 | 0.85 | KDM4E (0.51) | KDM4EMAPTKMT2AALDH1A1HPGD | |
| SCHEMBL4836085 | 0.85 | NPC1 (0.47) | KDM4EMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4825326 | 0.83 | LTB4R (0.48) | KDM4EMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4825333 | 0.83 | LTB4R (0.48) | KDM4EMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL2268362 | 0.81 | NR1H4 (0.54) | KDM4EMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL2274003 | 0.81 | HDAC2 (0.66) | KDM4EMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL12117935 | 0.81 | HPGD (0.44) | MCHR1KDM4EMAPTSMN1; SMN2MEN1 | |
| SCHEMBL2269617 | 0.80 | KDM4E (0.54) | KDM4EMAPTSMN1; SMN2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070584-A1 | Substituted aryloximes | AHR, NQO1, AOX1 | MCHR1 2217/4885KDM4E 509/4885MAPT 4769/4885 |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | HCCS, AOX1, TET2 | MCHR1 817/4885KDM4E 598/4885MAPT 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.